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both groups, but IG patients showed an earlier control
(61.8% control in IG vs 36.4% in CG at 12 weeks; p =
0.038). 2) INFONET Program: The ﬁrst 250 SMS were
analysed. Percentages of SMS sent by physicians were:
support (50.3%), Therapeutic compliance (2.7%),
Asking for data (29.5%), Scheduling visits to surgery
(6.0%), Modifying medication (1.6%), Others (9.9%).
The most frequent scheduling was one SMS every 12
days. CONCLUSIONS: In the usual practice (INFONET
Program), physicians use the SMS system in a different
way than predicted (HTA-Alert). They tend to give
support and to ask for data, instead of addressing com-
pliance and life-habits messages. Frequency of messages
was also lower. The use of SMSs seems to be a useful tool
for educational programs, and it would be convenient to
explore in more detail its effectiveness in health outcomes.
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OBJECTIVES: To establish the effect of a pharmaceuti-
cal care program on compliance and persistence with
once-daily atorvastatine treatment in patients with ele-
vated cholesterol levels. METHODS: An open-label,
prospective controlled trial of 1-year duration was con-
ducted in Belgium, stratiﬁed by language region. A French
speaking and a Flemish speaking region were randomized
to a Measurement Guided Medication Management
(MGMM) intervention consisting of review by the
patients’ pharmacist of the electronically compiled dosing
history, a “beep-card” that reminds patient of the dosing
time and educational reminders. The control group
received care as usual, also stratiﬁed between the 2
regions. Compliance was measured in all patients using
the Medication Event Monitoring System (MEMS®,
AARDEX, Switzerland), deﬁned as the % doses taken as
prescribed (once-daily). Nonpersistence was deﬁned as
the % of patients who stopped using atorvastatine before
the end of the study. Because of the skewed nature of
compliance data, statistical reporting includes medians,
25–75% interquartile ranges, and non-parametric tests.
RESULTS: A total of 393 patients were included: inter-
vention group: n = 194, control group: n = 199. After 1-
year follow-up and stratiﬁcation by region, the median %
of doses taken as prescribed (25% quartile–75% quartile)
was 96.1 (92.7–98.2) in the intervention group versus
89.9 (77.1–95.6) in the control group (p < 0.0001). Other
compliance variables showed similar results % prescribed
doses taken: 98.9 (96.3–100.3) vs 95.2 (83.0–98.9), p <
0.001, % doses within prescribed interval ±25%: 92.8
(85.9–95.9) vs 84.4 (63.0–92.5), p < 0.001 and Thera-
peutic Coverage: 96.1 (92.9–97.8) vs 93.6 (84.6–96.6), 
p < 0.001. Persistence was signiﬁcantly better in the inter-
vention group: 87.1% vs 76.9% in the control group 
(p = 0.02). Explanatory analysis showed that the Flemish
patient group and an elevated cardiovascular risk score
were signiﬁcantly related to better compliance and per-
sistence. CONCLUSIONS: Measurement Guided Med-
ication Management improved patient compliance and
persistence with atorvastatine.
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OBJECTIVE: Troponin T levels (TnT) predict hard
ischemic events and prognosis in patients (p) with unsta-
ble angina (UA) or non ST-segment elevation myocardial
infarction (NSTEMI). There are no reports on their
ability to predict the development of heart failure (HF) in
that population. METHODS: In order to determine the
ability of TnT to predict the incidence of NYHA class III
or IV HF along three months after an episode of unsta-
ble UA or NSTEMI, TnT levels were measured to 352 p
between the ﬁfth and 24th hour from hospital admission
due to an acute episode attributable to such diagnosis,
being 231 men and 121 women, mean age 67.6 years
(range 20 to 88). Personal or phone interview of patients
or relatives were obtained three months after the acute
episode looking for signs or symptoms of advanced heart
failure. RESULTS: TnT levels were higher than or equal
to 0.1ng/ml in 135p (TnT+ group) and less than 
0.1ng/ml in the other 217p (TnT- group). Both groups
were comparable in age (69 vs 66) and slightly different
in proportion of women (42% vs 32%). Three patients
died after episodes of class IV HF and all three pertained
to the TnT+ group. Odds ratios (OR) and their 95% con-
ﬁdence intervals (Cl) for the development of class III or
IV HF are reﬂected in the table. CONCLUSIONS:
Patients admitted with the diagnosis of unstable angina
or non ST-segment elevation myocardial infarction have
much more episodes of advanced heart failure in the fol-
lowing three months when Troponin T levels are elevated
in the ﬁrst 24 hours of the acute ischemic episode. TnT+
TnT- n(%) n(%) OR 95%CI p NYHA III/IV 11(8.9)
5(2.4) 3.85 1.3–11.3 < 0.03 NYHA IV 7(5.5) 2(0.9) 5.88
1.2–28.7 < 0.05.
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